Impact of Cholesterol on ABC and SLC Transporters Expression and Function and its Role in Disposition Variability to Lipid-Lowering Drugs

• Bogman K , PeyerAK, TörökM, KüstersE, DreweJ: HMG-CoA reductase inhibitors and P-glycoprotein modulation.Br. J. Pharmacol.132(6) , 1183–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Boyd RA , SternRH, StewartBH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.J. Clin. Pharmacol.40(1) , 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Wu X , WhitfieldLR, StewartBH: Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.Pharm. Res.17(2) , 209–15 (2000).
   PubMed Web of Science ®Google Scholar
• Chen C , MirelesRJ, CampbellSD et al.: Differential interaction of 3-hydroxy-3-methylglutaryl-coA reductase inhibitors with ABCB1, ABCC2, and OATP1B1.Drug Metab. Dispos.33(4) , 537–546 (2005).
   PubMed Web of Science ®Google Scholar
• Ito K , SuzukiH, HorieT, SugiyamaY: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.Pharm. Res.22 , 1559–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Rodrigues AC , CuriR, BrittoLR et al.: Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells.Biochim. Biophys. Acta1760(12) , 1866–1873 (2006).
   PubMed Web of Science ®Google Scholar
• Li HY , AppelbaumFR, WillmanCL et al.: Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood101(9) , 3628–3634 (2003).
   PubMed Web of Science ®Google Scholar
• Connelly-Smith L , PattinsonJ, GrundyM et al.: P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.Exp. Hematol.35(12) , 1793–800 (2007).
   PubMed Web of Science ®Google Scholar
• Thiebaut F , TsuruoT, HamadaH, GottesmanMM, PastanI, WillinghamMC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proc. Natl Acad. Sci. USA84(21) , 7735–7738 (1987).
   PubMed Web of Science ®Google Scholar
• Fromm MF , KauffmannHM, FritzP et al.: The effect of rifampin treatment on intestinal expression of human MRP transporters.Am. J. Pathol.157(5) , 1575–1580 (2000).
   PubMed Web of Science ®Google Scholar
• Maliepaard M , SchefferGL, FaneyteIF et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.Cancer Res.61(8) , 3458–3464 (2001).
   PubMed Web of Science ®Google Scholar
• Boyd RA , SternRH, StewartBH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.J. Clin. Pharmacol.40(1) , 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Westphal K , WeinbrennerA, ZschiescheM et al.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.Clin. Pharmacol. Ther.68(4) , 345–355 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarz UI , HansoH, OertelR et al.: Induction of intestinal P-glycoprotein by St John‘s wort reduces the oral bioavailability of talinolol.Clin. Pharmacol. Ther.81(5) , 669–678 (2007).
   PubMed Web of Science ®Google Scholar
• Giessmann T , MayK, ModessC et al.: Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.Clin. Pharmacol. Ther.76(3) , 192–200 (2004).
   PubMed Web of Science ®Google Scholar
• Mealey KL : Therapeutic implications of the MDR-1 gene.J. Vet. Pharmacol. Ther.27(5) , 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Chen C , LinJ, SmolarekT, TremaineL: P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.Drug Metab. Dispos.35(10) , 1725–1729 (2007).
   PubMed Web of Science ®Google Scholar
• Rebecchi IM , RodriguesAC, AraziSS et al.: ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.Biochem. Pharmacol.77(1) , 66–75 (2009).
   PubMed Web of Science ®Google Scholar
• Niemi M , ArnoldKA, BackmanJT et al.: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.Pharmacogenet. Genomics16(11) , 801–808 (2006).
   PubMed Web of Science ®Google Scholar
• Bernsdorf A , GiessmannT, ModessC et al.: Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.Br. J. Clin. Pharmacol.61(4) , 440–450 (2006).
   PubMed Web of Science ®Google Scholar
• Oswald S , HaenischS, FrickeC et al.: Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.Clin. Pharmacol. Ther.79(3) , 206–217 (2006).
   PubMed Web of Science ®Google Scholar
• Oswald S , WestrupS, GrubeM, KroemerHK, WeitschiesW, SiegmundW: Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats.J. Pharmacol. Exp. Ther.318(3) , 1293–1299 (2006).
   PubMed Web of Science ®Google Scholar
• Hirano M , MaedaK, MatsushimaS et al.: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.Mol. Pharmacol.68(3) , 800–807 (2005).
   PubMed Web of Science ®Google Scholar
• Grube M , KockK, OswaldS et al.: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart.Clin. Pharmacol. Ther.80(6) , 607–620 (2006).
   PubMed Web of Science ®Google Scholar
• Couvert P , GiralP, DejagerS et al.: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.Pharmacogenomics9(9) , 1217–1227 (2008).
   PubMed Web of Science ®Google Scholar
• Thompson JF , ManM, JohnsonK et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response.Pharmacogenomics J.5(6) , 352–358 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson TA : Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.Am. J. Cardiol.94(9) , 1140–1146 (2004).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , NiemiM, BackmanJT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin. Pharmacol. Ther.80(6) , 565–581 (2006).
   PubMed Web of Science ®Google Scholar
• Tobert JA : Efficacy and long-term adverse effect pattern of lovastatin.Am. J. Cardiol.62(15) , 28J–34J (1988).
   PubMed Web of Science ®Google Scholar
• Storch CH , EhehaltR, HaefeliWE, WeissJ: Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.J. Pharmacol. Exp. Ther.323(1) , 257–264 (2007).
   PubMed Web of Science ®Google Scholar
• Telbisz A , MullerM, Ozvegy-LaczkaC et al.: Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.Biochim. Biophys. Acta1768(11) 2698–2713 (2007).
   PubMed Web of Science ®Google Scholar
• Troost J , LindenmaierH, HaefeliWE, WeissJ: Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.Mol. Pharmacol.66(5) , 1332–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Rodrigues AC , GenvigirFDV, AraziSC et al.: Alteration of the expression of efflux and uptake transporters during hypercholesterolemia. Role in variability of atorvastatin response. Presented at: 4th Biologie Prospective Santorini Conference, Santorini, Greece, September 21–23 (2008).
   Google Scholar
• Shu Y , LiuH: Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.Biochem. Cell Biol.85(5) , 638–646 (2007).
   PubMed Web of Science ®Google Scholar
• Storch CH , KlimmHD, HeinrichT, HaefeliWE, WeissJ: Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells.Naunyn Schmiedebergs Arch. Pharmacol.376(1–2) , 135–143 (2007).
   PubMed Web of Science ®Google Scholar
• Dias V , RibeiroV: The expression of the solute carriers NTCP and OCT-1 is regulated by cholesterol in HepG2 cells.Fundam. Clin. Pharmacol.21(4) , 445–450 (2007).
   PubMed Web of Science ®Google Scholar
• Chavanet P , JolyV, RigaudD, BolardJ, CarbonC, YeniP: Influence of diet on experimental toxicity of amphotericin B deoxycholate.Antimicrob. Agents Chemother.38(5) , 963–968 (1994).
   PubMed Web of Science ®Google Scholar
• Bassissi MF , AlvinerieM, MartinPG, PerretB, LespineA: Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics.Pharm. Res.23(11) , 2672–2680 (2006).
   PubMed Web of Science ®Google Scholar
• Gardier AM , MathéD, GuédeneyX et al.: Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A.Ther. Drug Monit.15(4) , 274–280 (1993).
   PubMed Web of Science ®Google Scholar
• Ishizaki J , ItoS, JinM: Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B.Biopharm. Drug Dispos.29(4) , 195–203 (2008).
   PubMed Web of Science ®Google Scholar
• Dussault I , LinM, HollisterK, WangEH, SynoldTW, FormanBM: Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.J. Biol. Chem.276(36) , 33309–33312 (2001).
   PubMed Web of Science ®Google Scholar
• Kast HR , GoodwinB, TarrPT et al.: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.J. Biol. Chem.277(4) , 2908–2915 (2002).
   PubMed Web of Science ®Google Scholar
• Ebert B , SeidelA, LampenA: Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists.Carcinogenesis26(10) , 1754–1763 (2005).
   PubMed Web of Science ®Google Scholar
• Jigorel E , Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O: Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos.34(10) , 1756–1763 (2006).
   PubMed Web of Science ®Google Scholar
• Oscarson M , ZangerUM, RifkiOF, KleinK, EichelbaumM, MeyerUA: Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine.Clin. Pharmacol. Ther.80(5) , 440–456 (2006).
   PubMed Web of Science ®Google Scholar
• Maeda T , HirayamaM, HigashiR, SatoM, TamaiI: Characterization of human OATP2B1 (SLCO2B1) gene promoter regulation.Pharm. Res.23 , 513–520 (2006).
   PubMed Web of Science ®Google Scholar
• Stedman CA , LiddleC, CoulterSA et al.: Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.Proc. Natl Acad. Sci. USA102(6) , 2063–2068 (2005).
   PubMed Web of Science ®Google Scholar

▪ Websites

• GeNorm normalization of real-time PCR expression data http://medgen.ugent.be/genorm/
   Google Scholar
• Brazilian Census www.ibge.gov.br/home/
   Google Scholar